Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) ELISA Kits

PCSK9 encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. Zusätzlich bieten wir Ihnen PCSK9 Antikörper (165) und PCSK9 Proteine (55) und viele weitere Produktgruppen zu diesem Protein an.

list all ELISA KIts Gen GeneID UniProt
PCSK9 255738 Q8NBP7
PCSK9 100102 Q80W65
PCSK9 298296 P59996
Direkt bei antikoerper-online bestellen
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Online bestellen
  • orders@antikoerper-online.de

Top PCSK9 ELISA Kits auf antikoerper-online.de

Showing 10 out of 34 products:

Katalog Nr. Reaktivität Sensitivität Bereich Bilder Menge Lieferzeit Preis Details
Ratte 46.88 pg/mL 93.75-6000 pg/mL Typical standard curve 96 Tests 15 bis 18 Tage
$910.56
Details
Affe 1.1 pg/mL 1.1-800 pg/mL Typical standard curve 96 Tests 15 bis 18 Tage
$1,026.67
Details
Human 0.114 ng/mL 0.31 ng/mL - 20 ng/mL 96 Tests 13 bis 16 Tage
$736.84
Details
Maus 6.0 pg/mL 15.6 pg/mL - 1000 pg/mL 96 Tests 13 bis 16 Tage
$757.89
Details
Kaninchen 0.188 ng/mL 0.31 ng/mL - 20 ng/mL A typical standard curve 96 Tests 13 bis 16 Tage
$576.62
Details
Schwein 0.469 ng/mL 0.781-50 ng/mL Typical standard curve 96 Tests 12 bis 14 Tage
$715.00
Details
Meerschweinchen 0.094 ng/mL 0.15 ng/mL - 10 ng/mL A typical standard curve 96 Tests 13 bis 16 Tage
$641.23
Details
Huhn 4.688 ng/mL 7.813-500 ng/mL   96 Tests 12 bis 14 Tage
$715.00
Details
Human 0.12 ng/mL n/a   96 Tests 11 bis 16 Tage
$673.75
Details
Hund
  96 Tests 15 bis 18 Tage
$707.14
Details

Am meisten referenzierte PCSK9 ELISA Kits

  1. Rat (Rattus) PCSK9 ELISA Kit für Competition ELISA - ABIN820114 : Sucajtys-Szulc, Szolkiewicz, Swierczynski, Rutkowski: Up-regulation of liver Pcsk9 gene expression as a possible cause of hypercholesterolemia in experimental chronic renal failure. in Molecular and cellular biochemistry 2016 (PubMed)
    Show all 3 Pubmed References

  2. Mouse (Murine) PCSK9 ELISA Kit für Sandwich ELISA - ABIN2685159 : Seidah, Benjannet, Wickham, Marcinkiewicz, Jasmin, Stifani, Basak, Prat, Chretien: The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. in Proceedings of the National Academy of Sciences of the United States of America 2003 (PubMed)
    Show all 3 Pubmed References

  3. Human PCSK9 ELISA Kit für Sandwich ELISA - ABIN2345049 : Jin, Park, Kim, Vaziri: Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study. in American journal of kidney diseases : the official journal of the National Kidney Foundation 2014 (PubMed)
    Show all 3 Pubmed References

  4. Rabbit PCSK9 ELISA Kit für Sandwich ELISA - ABIN5521366 : Elseweidy, Amin, Atteia, El-Zeiky, Al-Gabri et al.: New Insight on a Combination of Policosanol and 10-Dehydrogingerdione Phytochemicals as Inhibitors for Platelet Activation Biomarkers and Atherogenicity Risk in Dyslipidemic Rabbits: Role of CETP and ... in Applied biochemistry and biotechnology 2019 (PubMed)
    Show all 2 Pubmed References

  5. Rat (Rattus) PCSK9 ELISA Kit für Sandwich ELISA - ABIN434248 : Shafik, Baalash, Ebeid: Synergistic Cardioprotective Effects of Combined Chromium Picolinate and Atorvastatin Treatment in Triton X-100-Induced Hyperlipidemia in Rats: Impact on Some Biochemical Markers. in Biological trace element research 2017 (PubMed)

Weitere ELISA Kits für PCSK9 Interaktionspartner

Human Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Interaktionspartner

  1. Study showed that plasma PCSK9 concentrations increase transiently over time in septic and non-septic critically ill patients and demonstrated that PCSK9 negatively regulates LDLR-mediated uptake of bacterial lipoteichoic acid (LTA) and lipopolysaccharide (LPS) by HepG2 hepatocytes through a lipoprotein (LDL)-dependent mechanism, whereas LRP1 and high-density lipoprotein do not contribute to this uptake pathway.

  2. In patients with potential familial hypercholesterolemia, positive correlations between concentrations of Lp(a) and PCSK9, as well as of Lp(a)-PCSK9 plasma complex with large subfractions of intermediate and low-density lipoproteins (IDL-1 and LDL-C), were determined by the low molecular weight apo(a) phenotype.

  3. rare variants in LDLR and PCSK9 were associated with the onset age of MI by altering LDL-cholesterol levels

  4. Acute-phase plasma PCSK9 levels are associated with levels of inflammation and triglycerides, premature coronary heart disease, and gender in acute myocardial infarction patients without reperfusion therapy. However, it does not predict recurrent cardiovascular events at 1 year.

  5. Thus, it is evident that sauchinone reduces hepatic steatosis by downregulating the expression of hepatic PCSK9 via SREBP-2.

  6. PCSK9 plays a role lipoprotein metabolism and atherosclerotic cardiovascular disease. Review.

  7. in patients with acute myocardial infarction, plasma PCSK9 levels measured during the acute phase predict recurrent cardiovascular events within 1 year

  8. The results of the current meta-analysis for the first time indicated the relevance of rs562556 of PCSK9 and lower serum cholesterol levels.

  9. Associations for BCO2, PCSK9, and TR1B1 Polymorphism and Lifestyle Factors with Ischemic Stroke

  10. PCSK9 association with intestinal secretion and plasma overaccumulation of TRL apoB-48 in men with IR

  11. PCSK9 may regulate LOX-1 mediated ox-LDL uptake by the THP-1 derived macrophage via TLR4/NF-kappaB/COX-2/ROS pathway

  12. Pathogenic mutations in LDLR, APOB, PCSK9 and LDLRAP1 genes were found in 17 of 225 patients with familial hypercholesterolemia leading to premature myocardial infarction.

  13. Variants at the PCSK9 gene locus seem to be the major genetic determinants of plasma PCSK9 levels.

  14. Elevated serum level of PCSK9 can be observed in systemic lupus erythematosus patients, especially in those with thickening of carotid intima-media.

  15. Identification and in vitro characterization of two new PCSK9 Gain of Function variants found in patients with Familial Hypercholesterolemia.

  16. Demonstration of an interaction between PCSK9 and ATF-2, which reduces ATF-2/c-Jun dimerization and ATF-2/c-Jun binding to the IFNbeta enhancer. This novel function of PCSK9 should have important implications in optimizing the clinical use of PCSK9 inhibitors.

  17. In this study, the appropriate virus-like particle (VLP)-peptide vaccines targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) were screened. The screening criteria of target peptides were as follows: located in catalytic domain of PCSK9, or regulating the binding of PCSK9 and LDL receptors (LDLR)

  18. This finding is associated with a profound FH phenotype and the highest known plasma PCSK9 level reported in a human. This finding also has therapeutic relevance, as elevated PCSK9 levels may limit the efficacy of high-dose statin therapy and also PCSK9 inhibition

  19. PCSK9-mAbs could significantly reduce circulating Lp(a) levels.

  20. We conclude that the PCSK9 R496W (rs374603772) and D374Y (rs137852912) GOF mutations may be significant risk factors in the development of primary dyslipidemia and may have significant impact on lipid parameters in general population.

Mouse (Murine) Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Interaktionspartner

  1. Glucagon-Gcgr-Epac2-Rap1 pathway regulates plasma LDL-C metabolism by controlling PCSK9 degradation.

  2. PCSK9 is up-regulated in the ischaemic hearts and determines development of infarct size, cardiac function, and autophagy.

  3. In an inflammatory milieu, elevated levels of PCSK9 potently stimulate the expression of scavenger receptors (principally LOX-1) and ox-LDL uptake in macrophages, and thus contribute to the process of atherogenesis.

  4. The absence of PCSK9 in LDb mice results in decreased lipid and apoB levels, fewer atherogenic LDLs, and marked reduction of atherosclerosis.

  5. In this study, the appropriate virus-like particle (VLP)-peptide vaccines targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) were screened...PCSK9Qbeta-003 vaccine obviously decreased plasma total cholesterol in both Balb/c mice and LDLR(+/-) mice

  6. In the present study, it was investigated whether ticagrelor reduces oxidized lowdensity lipoprotein (oxLDL)induced endothelial cell apoptosis, an initial step for the development of atherosclerosis(AS), and alleviates AS in apolipoproteinEdeficient (ApoE/) mice by inhibiting the expression of proprotein convertase subtilisin/kexin type 9 (PCSK9)

  7. We observed long-term postnatal persistence of edited cells in both models, with reduction of plasma PCSK9 and cholesterol levels following in utero Pcsk9 targeting and rescue of the lethal phenotype of hereditary tyrosinemia type 1 following in utero Hpd targeting

  8. High PCSK9 expression is associated with atherosclerosis and liver cancer.

  9. Given that overexpression of these LOF PCSK9 variants does not cause UPR activation under normal homeostatic conditions, therapeutic strategies aimed at blocking the autocatalytic cleavage of PCSK9 in the ER represent a viable strategy for reducing circulating PCSK9

  10. Data suggest that expression of Pcsk9 and Ldlr in liver and pancreas can be regulated by dietary measures; here, dietary supplementation with quercetin-3-glucoside modulates expression of Pcsk9 and Ldlr in prevention of hyperlipidemia and hyperinsulinemia induced by high dietary cholesterol. (Pcsk9 = proprotein convertase subtilisin/kexin type-9; Ldlr = low-density lipoprotein receptor)

  11. The data of the present study demonstrated that the PCSK9 shRNAmediated antiapoptotic effect induced by MCAO in hyperlipidemic mice is associated with ApoER2 downregulation, which may be a potential new therapy for stroke treatment in patients with hyperlipidemia.

  12. It was concluded that quercetin inhibits oxLDLinduced lipid droplets in RAW264.7 cells by upregulation of ABCAl, ABCG1, LXRalpha and downregulation of PCSK9, p53, p21 and p16.

  13. PCSK9 overexpression in the aorta may promote acute aortic dissection.

  14. Genetically determined PCSK9 deficiency might be associated with ectopic fat accumulation.

  15. The present study aimed to explore the direct toxicity of proprotein convertase subtilisin/kexin type 9 (PCSK9) to atherosclerosis (AS) and its association with apoptotic endothelial cells.

  16. present anti-PCSK9 vaccine induced long-lasting anti-PCSK9 antibody production and improved lipoprotein profiles. Thus, anti-PCSK9 vaccine could become a new option for the treatment of dyslipidemia as a long-acting therapy in future

  17. PCSK9 may act as an inflammatory mediator in the pathogenesis of atherosclerosis via TLR4/NF-kappaB signaling pathway.

  18. PCSK9, by sustaining smooth muscle cell synthetic phenotype, proliferation, and migration, may play a pro-atherogenic role in the arterial wall

  19. PCSK9 inhibits lipoprotein(a) clearance through the LDLR.

  20. Use Crispr-Cas system to introduce nonsense variants into PCSK9 to lower blood cholesterol levels.

Pig (Porcine) Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Interaktionspartner

  1. the PCSK9-gain-of-function mutation induces rapid development of atherosclerosis in peripheral vessels of Ossabaw pigs, which is exacerbated by a high-cholesterol diet.

PCSK9 Antigen-Profil

Beschreibung des Gens

This gene encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. The encoded protein is synthesized as a soluble zymogen that undergoes autocatalytic intramolecular processing in the endoplasmic reticulum. The protein may function as a proprotein convertase. This protein plays a role in cholesterol homeostasis and may have a role in the differentiation of cortical neurons. Mutations in this gene have been associated with a third form of autosomal dominant familial hypercholesterolemia (HCHOLA3).

Genbezeichner und Symbole assoziert mit PCSK9

  • proprotein convertase subtilisin/kexin type 9 L homeolog (pcsk9.L) Antikörper
  • proprotein convertase subtilisin/kexin type 9 (pcsk9) Antikörper
  • proprotein convertase subtilisin/kexin type 9 (PCSK9) Antikörper
  • proprotein convertase subtilisin/kexin type 9 (Pcsk9) Antikörper
  • AI415265 Antikörper
  • AI747682 Antikörper
  • FH3 Antikörper
  • HCHOLA3 Antikörper
  • LDLCQ1 Antikörper
  • NARC-1 Antikörper
  • Narc1 Antikörper
  • PC9 Antikörper

Bezeichner auf Proteinebene für PCSK9

proprotein convertase subtilisin/kexin type 9 , convertase subtilisin/kexin type 9 preproprotein , neural apoptosis regulated convertase 1 , subtilisin/kexin-like protease PC9 , NARC-1 , convertase subtilisin , neural apoptosis-regulated convertase 1 , proprotein convertase 9 , proprotein convertase PC9 , proprotein convertase subtilisin/kexin type 9 preproprotein , Proprotein convertase 9 , Subtilisin/kexin-like protease PC9

GENE ID SPEZIES
495509 Xenopus laevis
100150316 Danio rerio
100544916 Meleagris gallopavo
255738 Homo sapiens
100102 Mus musculus
298296 Rattus norvegicus
424664 Gallus gallus
100731533 Cavia porcellus
717147 Macaca mulatta
100971792 Pan paniscus
456880 Pan troglodytes
100395116 Callithrix jacchus
100620501 Sus scrofa
Ausgewählte Anbieter für PCSK9 (PCSK9) ELISA Kits
Haben Sie etwas anderes gesucht?